Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 2 Interventional

Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma

ClinicalTrials.gov ID: NCT03400917

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03400917. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial of Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens (AV-GBM-1) as an Adjunctive Therapy Following Primary Surgery Plus Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a single-arm, open-label phase II clinical trial in which approximately 55 patients with newly diagnosed glioblastoma (GBM) will be enrolled with the intent to receive an autologous dendritic cell vaccine consisting of autologous dendritic cells loaded with autologous tumor-associated antigens (AV-GBM-1).

Study identification

NCT ID
NCT03400917
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Aivita Biomedical, Inc.
Industry
Enrollment
55 participants

Conditions and interventions

Interventions

Biological

Eligibility (public fields only)

Age range
18 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 20, 2018 (Actual)
Primary completion
Dec 1, 2021 (Actual)
Completion
Feb 2023 (Estimated)
Last update posted
Dec 16, 2021

2018 – 2023

United States locations

U.S. sites
8
U.S. states
3
U.S. cities
7
Facility City State ZIP Site status
Scripps Health La Jolla California 92037 —
UC San Diego Moores Cancer Center La Jolla California 92037 —
Hoag Memorial Hospital Presbyterian Newport Beach California 92663 —
UC Irvine Medical Center Orange California 92868 —
UC Davis Comprehensive Cancer Center Sacramento California 95817 —
John Wayne Cancer Institute Santa Monica California 90404 —
Norton Cancer Institute Louisville Kentucky 40202 —
Rutgers Cancer Institute New Brunswick New Jersey 08903 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03400917, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2021 · Synced Nov 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.